INISIGHT | OUTCOMES | VALUE

The use of AI for health outcomes predictalytics as a foundation for Value Based Healthcare (VBHC)

Matt Hickey BHScMRT, PGSM DocClinPrac*

Senior Radiotherapist

- CEO Intacare International Ltd
- CEO The Health Value Partnership

Scene setting





"Without data you're just another person with an opinion."

- W. Edwards Deming, Data Scientist



Different perspectives on 'benefit and 'value'

The benefit of any medical innovation can only truly be measured by the benefit to the patient, <u>as they see it</u>! Dr Don Berwick – Advisor, World Health Organisation

When assessing the value of any intervention we must not look solely at whether the patient <u>lived</u> as a result but rather whether they lived (or died) <u>'well'.</u>

Public Health England

At the beginning of any decision process one must always consider the perspectives of the different stakeholders, and then balance where the value lies for each.

P. Just: PharmD, Senior Principal, Global Health Economics. ICON

- Payers: €, QALY, DALY, ICER
- Hospitals: Admissions, length of stay, volume of interventions, AEs
- Clinicians: OS, DFS, PSF,
- **Patients:** Quality of life, functional ability, emotional well-being, time

Limited Understanding: About how decision are made- what data?

The result: Instability and poor 'value exchange', a cycle of diminishing returns

The Data Challenge




Core clinical parameters	
Demographics	Personal History
• Co-morbidities	Presenting symptoms profile
 Diagnosis dataset – time, methodology, accuracy 	Treatment Dataset - Sx, CT, RT, HRT, IT etc
 Regime(s) / protocol(s) incl. Trial e.g. FEC, CHHiP 	Dose, timing, duration, OAR dose, multi-modalities
Treatment Dataset - Sx, CT, RT, HRT, IT etc	 Regimen(s) / protocol(s) incl. Trial e.g. FEC, CHHiP
 Acute and longitudinal toxicity profiles (RTOG / CTCAE) 	Survivorship data: OS, PSF, DFS, date of death etc
Adverse event reporting	Longitudinal health data
Clinical Coding	Ontologies
• ICD-10	• SNOMED-CT
Toxicity Scoring	Clinical Data Systems
RTOG, UKONS, CTCAE	EMR, OIS + AE reporting
Patient Reported Outcomes	Patient Reported Experience
380 different questionnaire suites	Numerous
Claims / Cost datasets / models	Claims Systems
UK CCSD, ICS, HRG, QALY, ICER, DALY, QOCRV	CREST, CIARA, Lorica
Benchmarks - national	Benchmarks - International
 PHE (COSD, RTDS, PCDS, NatPatSatQ) + ICHOMs, CODE, SAMS, PIE, others 	• OECD – others

In the above, how well does does patients voice REALLY feature?

The Time Challenge





Compared to the standard treatment, both alternatives (treatment B and C) are more costly in the short-term. But, when evaluated as total treatment cost over time, treatment B is cost saving after eight months - but cost more in total Treatment C is cost saving beyond two years and gives most return in the long term

Introducing Intacare





The company:

- A clinical AI and data science company dedicated to developing clinical risk prediction solutions that optimise outcomes for multiple stakeholders
- · The patients voice remains central to everything we do

Aim:

To socialise the science of predictalytics in VBHC

Vision:


 To be the 'google maps' for clinical outcomes – enabling better value navigation by providing a 'value map' that transcends the healthcare ecosystem

History:

- Seven years of academic research (Imperial College London, University of Surrey)
- Three clinical pilots (Royal Marsden, Royal Surrey, Southampton NHS Trusts partnered with Varian and Macmillan)
- Commercial pilots (GenesisCare UK (10 Sites) + Varian)
- Now linking to the largest insurer in the world and the largest oncology-tech solution in the world

Intacare AI – Predictive Risk and Outcomes Insights Engine (PIE)





Liberate academic knowledge

Identify the data that is both necessary and currently available to enable the application of real world insights for complex decision support, risk assessment, tracking and mitigation and cost/benefit identification.

Target data from multiple datasets

Use AI and machine learning-based system to apply predefined academic logic to defined datasets to present risk reports that are tailored to the subscribers needs.

Federated learning

Provide a secure cloud-based SaaS risk engine to interact with third-party data collection suites and analysed data to elicit dynamic decision aids to put these at he finger-tips of the decision makers

Patient-Centricity Simplifying patient reported outcomes and making them diagnostic and dynamic

Precision

Superior clinical decision support and insights built from the latest evidence

Prediction

Predicting events, eliciting better value across the ecosystem for value-based reimbursement and performance incentives

Value

Defined value outputs optimized for Value-Based Healthcare and cost transparency

Intacare AI – Academic Programme 1: Cancer Dynamic (diagnostic and predictive) PROMs



Question: What is the most comprehensive holistic PROM that correlates with late effects

- Identify: Most comprehensive symptoms toolkit that covers key holistic domains: Symptoms, psychosocial, vocational, spiritual / Quality of Life (Rotterdam) What symptoms are missing
- Process:Combined 380 PROMs tools.Correlated PROM with patient characteristics + clinical data + toxicity dataIdentified what symptoms are most indicative of a clinical eventAcademically and clinically validated = 19
- **Develop**: A new, hybrid and all encompassing toolkit with a new, more meaningful presentation structure (Intacare SAMS):
 - Correlates with late effects prediction
 - Validated for clinical and academic use.

test	lii .
residen	140.01
tau harn	2401
whole Quality of Life Durationnaire Alerta	
*	-
Same in the	(include

Intacare AI – Academic Programme 1: Cancer Dynamic (diagnostic and predictive) PROMs



test .	16
resident	140.01
have been	2401
white Quality of Life Questionnaire Alerts	
iei	-
Latered in the	(include

Presents:

- Specific symptom severity Heatmaps
- +/- trends
- Cancer-specific symptom clusters , breaches
- Identifies early sign of recurrence
- Identifies risk and early signs of critical events



Intacare AI – Academic Programme 2: Cancer late effects prediction models (predictalytics)



Inception:	What are the data that are associated with a late effect risk /
	presentation. How to target these data to predict future events

- Assess: Academic literature (100's of evidence level I and II papers) relating to toxicity and late effects
- Analyses: Disparate datasets and targets defined data (precision data)
- Filters: Data into international ontologies and coding structures (ICD etc)
- **Correlates:** Patient characteristics + clinical data + utility data + toxicity data + Patient Reported Data (PROMs) + Patient Satisfaction Data (PREMs)
- Identify:The symptoms assessed in the report, importance use
Patient characteristics + clinical data + toxicity data
Determine what symptoms are most indicative of a clinical event
- **Develop:** A new, dynamic, late effects prediction and state change assessment model

Synchrome, Causation, Probability Analysis Reports	
lagt .	10C
(resolution)	140.01
sauture.	2-ie/01
Helistic Quality of Life Questionnaire Alerta	
iai	-
Carrier (10)	time in

Intacare AI – Academic Programme 2: Cancer late effects prediction models (predictalytics)



isk manageme	ent logic			Validate	Submit Can
Treatment mode	Acute effects	Late effects	Monitoring	PROMS	Remove?
Radiology C	Bowel dysfunction - diarhoea Bowel dysfunction - tenesmus Dystria Rotal bleeding Utray isocontence Utray isopancy Haematuria Pehic pain	Rectal bleeding Inogular bovel habit Stricture of the untilvia Erectile dysturction Maematuria Secondary malignancies	E-monthy PSA I2-monthy consult Advise patient to report new symptoms	Urivary symptoms Nocturia Filigue Weakness Breakissness General disability Sateltal pain Instability, change in mood, or confusion Operession Bowel dystunction - textal bleeding	Remove
Surgery \$	Bowel dysturction - diarhoea Bowel dysturction - tenesmus Oysuria Petuta bleeding Utimary incontinunce Utimary incontinunce Utimary incontinunce Winary Incontinunce Petuic pain	Rectal bleeding Iregular bovel habit Stricture of the untitiva Erectile dystunction Hermaturia Secondary malignancies	E-monthly PSA Temorthly consult Advise patient to report new symptoms	Urinary symptoms Nocturia Palgue Weakness Breathlessness General disability Savietal pain Initiability, change in mood, or confusion Depression	Remove

Presents:

- The probability of late-effect (syndrome) e.g. cardiac, respiratory syndrome
- Identifies the associated / contributing risk factors
- Predicts the % probability of and time to occurrence
- Predicts the presentation e.g. myocardial infraction
- Proposes a monitoring plan e.g. monthly BP + weight +, 6-monthly MUGA LVEF
- Provides a link to the supporting evidence that the rule(s) was derived from

Syndrome, Causation, Probability Analysis Reports	Check Systems Moder C Assistant	Bandkome Causation, Probability Analysis Reports
Efforts Syndromes Monitor	Thack you. Your Hiputs have been received and triggered 19 percent integrals. With red of the anti-contention, executions is charge when to the content percent according to the 30 how the content percent percent	
Synkones Message	M 25 cat of geophyse science detached information of the reaches marche solited to: the and/or basely general proceeding to rais 100 from the samily benefability array regard	Effects Syndromets Monitor
The implify logner has intractised a risk for parelian apolytoms	New 4 a 12N privately of devinance for effect durations of treat, which is the carting spatial protect according to the 12N from the installational access spart	and the second
The transfer Singles has detected a till for inserving other spectrum.	31 Ph tab of spinotes per to the apple lasticelaries of a low low place period states of the test of the test of the last of the test of test of the test of t	
The trappy largest law with detected year for exact detected agramme.	12.0% rails of effect orbital to the peripheral managering system during the level 60 months according to use 120 host the management spranet	Mornine Metologie
The institution of the set deletion on the webships, and one-	10 Phys 20 Physical advector descending, such as detection of the contemporating parter within 102 meeting according to call (1) here the contemporated according to the US meeting according to call (1) here the contemporated according to the US meeting a	Munimumg har Lawthai aphiltamia oray mahala itawa 3 tauta
The traget larger has not detected the traget days applicates	10 Pixe (0.05 tot of which indial to the audio tomic types intering the used white 100 months according to the VD from the sector metabolic samp report	
The imagin Engranhae we delected risk for one palme equipment	particle of developing the effect percentiles inference for sector security securit according to six for their the partic metabolic same sport	Monttoing for income angenting ignations may second thread 42 takes.
The imaging fragine has not detected this by gastroomethod spottering.	particul with disponsioning the effect dependence (addression indexestion free section) systems; according to spicial from the particul methods in party	

Case Study: Research Programmes Simplifying Long-form PROMs & Predictalytics



Royal Marsden NHS Foundation Trust, UK: -Royal Surrey NHS Foundation Trust, UK: -

- 6-yr Prostate Brachytherapy multiple PROMs analysis (complete)
- 5-years Colorectal Cancer multi-PROMs analysis (July 2019)
- 5-years Prostate multi therapy data analysis (July 2019)

Aims:

- Assess the correlation between treatment characteristics (dose etc), patient characteristics (age), patient's own perception of health
- Patterns in symptoms presentation against time, the individual and their treatment characteristics
- Identify symptoms that are typical in this cohort and indicate toxicity and declining Quality of Life
- Map to Predictive Insights Engine for late effects correlation

Royal Marsden Review:

Final Cohort analysed:	94 men who had been treatment with prostate brachytherapy between 2006 – 2013 (mean age: 64-yrs)
PROMs data:	EPIC, FACT-P(v4), IPSS, Fulham questionnaires (full or partial) at baseline, 6-months, 1, 5, 6 years
Treatment system data:	Age at treatment, Total Target Dose D100 (Gy), Target dose D90 (Gy), Rectal Volume (cm3), Rectum dose D100 (Gy), Urethra volume (cm3), Urethra dose D100 (Gy), Number of needles, Number of seeds
Key Missing data:	Patient stage and grade

Analysis:

- 1. PROM response timeline
- 2. Features importance
- 3. Cluster longitudinal analysis of correlating factors and response
- 4. Effect on other parameters

Symptoms	Correlation
↑ depression at 1 year Persistent depression	Number of needles, rectal vol, urethra vol, pain
Potency decline	Age, number of needles, urethra vol
Weight change at 6 months, 1 year	Age, potency decline, pain, depression
Pain (general)	Rectal vol, depression
Pain urinating	Urethra vol, depression
Nocturia at 1-year	Number of needles, urethra vol, depression

Predictive modelling - How will patients will answer PROM at each timepoint and what features are important


(Support Vector Regression with mean squared error (low = well performing)


Future Analysis:

- 1. Stage and Grade correlations
- 2. Analyse subset of patients who feel their pain gets worse over time
- 3. Run targeted PROM against new PROM Protocol using EORTC-QOL PR25 to further develop predictive model




Pain urinating_6mt Pain urinating_1yr	 Numi Numi Recta Recta 	Feature at Treatment ber of needles implanted ber of seeds implanted al Volume (cm3) um D1cc (Gy)		an san san san san san san san san san s			
Wake to pee	Targe	et D100 (Gy) et D90 (Gy) hra Volume (cm3)	•	$(a,b) \in \mathbb{R}^{n}$		÷	
Wake to pee_6mt							
Wake to pee_lyr			1.1	·•	•		
Depressed				11 June -			
Depressed_6mt	•		1	* * · ·			
Depressed_lyr				Sec. 1			
Weight Change				Sec. 1			
Weight Change_6mt				1.1.1.1	1		
Weight Change_1yr		•		1.000			
	-0.4	-0.	2	0.0 Feature Importance	0.2	0	14





Intacare AI – Dynamic Risk and Value Engine (RaVE)





Aim:

- Provide a multi-sided digital QOCRV insights platform
- Improve consumer and provider risk profiling
- A secure medium of exchange for healthcare outcomes and valuebased payment communication
- A machine learning platform for identifying unwarranted variation, fraud, waste and abuse

Analyses:	Disparate claims / cost datasets
Filters:	Data into standardised coding - coding (ICD / HRG / CCSD)
Correlates:	Patient characteristics + clinical data + utility data + toxicity data + Patient Reported Data (PROMs) + Patient Satisfaction Data (PREMs) + cost / claims (by code)

Produces:

•

Bespoke targeted 'risk insights' to our subscribers Using standard industry health-economic measures e.g. Quality Adjusted Life Years, Daly Adjusted Life Years, ICER, Relative Live Value, Relative Risk, Utility and utility cost.

Case Study: Cost of Cancer Analysis



PMI providers (1 x New Zealand, 2 x UK): Typical Spend GBP £300m - 400m, NZD \$17m

Aims:

- 1. To determine the 'total cost of cancer', root cause of costs, establish mechanisms to assess, predict and mitigate cost risk
- 2. Establish Outcomes Based Commissioning Model for Targeted Commissioning from high performers

Process

- 1. Assess historic claims data (5-yrs) what are patients/ hospitals/ clinicians claiming for
- 2. How do these claims relate to typical toxicity / co-morbidity profiles
- 3. What are the characteristics of individuals treatment-related / patient-specific correlate with PIE
- 4. Where were they treated, by whom and with what (appropriateness)
- 5. Run some value models (QALYs, ICERs, DALYs, TDABC, total cost of claim/ life, time, clustering's, Relative Life Value/Risk

Results:

- 1795 code narrative variations (standard CCSD model = 33)
- Wide variation in claims areas of significant suspected fraud, waste, abuse and unwarranted variation
- £44-56m in savings (UK): 14% savings (excl. operational efficiencies)

Next steps:

• New 'quality and value assurance' model mandated to all hospitals - includes PROMs and PIE dataset.

Summary



- The patients voice is diagnostic and predictive
- Captured via PROMs / PREMS and toxicity datasets
- Align our perspectives on 'benefit and 'value' ecosystem value exchange
- Standardize our datasets ensure PROMs / PREMs etc are central
- Include correlation between clinical, patient reported and cost/ utility data (transcending views)
- Identify root cause of value erosion evidence based best practice?
- Evolve the models for predictalytics (proactive not reactive care) let AI do the heavy lifting
- Socialised e.g. via ICHOMs
- Observe, learn, optimise, repeat...



Thank you

Matt Hickey

Senior Radiotherapist CEO - Intacare International Ltd CEO - The Health Value Partnership

www.intacare.com